TY - JOUR
T1 - Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry
AU - Gigliotti, Anna Rita
AU - Di Cataldo, Andrea
AU - Sorrentino, Stefania
AU - Parodi, Stefano
AU - Rizzo, Antonino
AU - Buffa, Piero
AU - Granata, Claudio
AU - Sementa, Angela Rita
AU - Fagnani, Anna Maria
AU - Provenzi, Massimo
AU - Prete, Arcangelo
AU - D'Ippolito, Carmelita
AU - Clerico, Anna
AU - Castellano, Aurora
AU - Tonini, Gian Paolo
AU - Conte, Massimo
AU - Garaventa, Alberto
AU - De Bernardi, Bruno
PY - 2009/12
Y1 - 2009/12
N2 - Aim: Presenting features, treatment and outcome of 134 newborns with neuroblastoma diagnosed over a 27-year period are described. Methods: Analyses were performed on the entire cohort and on patients distributed over three periods of diagnosis. Results: Twenty-seven tumours (20.1%) were detected prenatally. Localised disease prevailed (65.7%) with an increase of stage 1 patients over time from 18.8% to 46.5%. Disseminated disease accounted for 34.3% of tumours with only one stage 4 and 45 stage 4S. Five-year overall survival (OS) of the entire cohort was 88.3%. Five/88 patients with localised disease died, including three who died of complications (OS, 95.3%). The only stage 4 patient survived. Eleven/45 stage 4S patients died, including 7/18 symptomatic and 4/27 asymptomatic (OS, 74.1%). Conclusion: The outcome of neuroblastoma in newborns is excellent. In localised tumours, surgery-related deaths outnumbered deaths due to disease. Symptomatic stage 4S patients were at greater risk of dying.
AB - Aim: Presenting features, treatment and outcome of 134 newborns with neuroblastoma diagnosed over a 27-year period are described. Methods: Analyses were performed on the entire cohort and on patients distributed over three periods of diagnosis. Results: Twenty-seven tumours (20.1%) were detected prenatally. Localised disease prevailed (65.7%) with an increase of stage 1 patients over time from 18.8% to 46.5%. Disseminated disease accounted for 34.3% of tumours with only one stage 4 and 45 stage 4S. Five-year overall survival (OS) of the entire cohort was 88.3%. Five/88 patients with localised disease died, including three who died of complications (OS, 95.3%). The only stage 4 patient survived. Eleven/45 stage 4S patients died, including 7/18 symptomatic and 4/27 asymptomatic (OS, 74.1%). Conclusion: The outcome of neuroblastoma in newborns is excellent. In localised tumours, surgery-related deaths outnumbered deaths due to disease. Symptomatic stage 4S patients were at greater risk of dying.
KW - Infant
KW - MYCN gene
KW - Neuroblastoma
KW - Newborn
KW - Prenatal diagnosis
KW - Stage 4S disease
UR - http://www.scopus.com/inward/record.url?scp=70450267587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70450267587&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2009.08.020
DO - 10.1016/j.ejca.2009.08.020
M3 - Article
C2 - 19767197
AN - SCOPUS:70450267587
VL - 45
SP - 3220
EP - 3227
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 18
ER -